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A 34-year-old woman at 28 weeks of gestation pre-
sented at the emergency department of our hospital
with shortness of breath, cough, sweating, and deterio-
ration of consciousness, which had begun 3 days ago.
The history given by her relatives revealed that she had
received intravenous ritodrine (later found to be in the
form of a constant infusion at 60 µg/min for 2 days)
together with two doses of betamethasone (Celestone,
Schering) at 12-hour intervals for accelerating fetal lung
maturation in a private clinic. After this initial interven-
tion, treatment was continued with oral tocolytic tablets
(ritodrine tablets). There was nothing else notable in her
medical history. Physical examination of the unconscious
patient revealed a body temperature of 37.2°C, arterial
blood pressure of 90/60 mmHg, pulse rate of 142/min,
and respiration rate of 27/min, with hyperventilation
and slight rales over bilateral lungs. She was intubated
immediately. Fetal measurements were concordant
with a 28-week pregnancy, and the amount of amni-
otic fluid was found to be normal. Ultrasonic estima-
tion of fetal weight was 1,100 g. The hemoglobin level,
hematocrit, leukocyte count and platelet counts were
12 g/dL, 37.2%, 9.100/mm3 and 223,000/mm3, respec-
tively. Plasma levels of glucose, urea, creatinine and
albumin were 164 mg/dL, 135 mg/dL, 3.4 mg/dL and
2.6g/dL, respectively. Arterial blood gas analysis revealed
hypoxia (PO2, 35.5 mmHg; SaO2, 68%) with acidosis
([HCO3],15mEq/dL; pH, 7.32) and hypocapnia (PCO2,
29.4). Chest X-ray revealed increased radiodensity in the
basal lobes of the lungs, predominantly on the left
side, and a diagnosis of noncardiogenic pulmonary
edema due to ritodrine treatment was proposed by
chest doctors. Ritodrine was stopped immediately, and
supportive therapy with prophylactic antibiotics, low-
dose diuretics, β-blocker agents, fluid intake restric-
tion and mechanical ventilation was started. However,
the patient died 10 hours after beginning the treat-
ment due to cardiac arrest, and negative fetal cardiac
activity was subsequently detected by ultrasound.
Many factors, such as the use of tocolytic agents,
cardiac disease, fluid overload and preeclampsia, have
been reported as risk factors in pregnant women for
the development of pulmonary edema [1,2]. Ritodrine
is the most commonly used agent among β-mimetics
for tocolytic treatment [3]. The incidence of pulmonary
edema arising from tocolytic treatment is about 4.4%,
and it usually develops during the second day of the
treatment. Infusions should be started at the lowest
dose possible, as long as specific information on plasma
clearance is not available. Caritis et al [4] addressed
the issue of dosage and defined the pharmacokinetics
of ritodrine in 13 pregnant women receiving the drug
by constant intravenous infusion at 50 µg/min. In their
series, two cases of acute pulmonary edema occurred 
3 hours after perfusion was stopped. Pulmonary edema
requiring mechanical ventilation support appears in
3–10% of cases. The mortality from pulmonary edema
is 3%, and this increases if sepsis and acute respiratory
distress syndrome complicate the situation [5].
Close monitoring and restriction of fluid intake can
prevent the development of pulmonary edema; but if it
develops, ritodrine treatment must be stopped imme-
diately. If the patient’s condition is serious, β-blockers
and loop diuretics should be used to antagonize the
effects of ritodrine and pulmonary edema. Controlled
intravenous fluid support, maintenance of the electrolyte
balance, adequate oxygenation, and support of respi-
ration with mechanical ventilation can be used, when
necessary, for the treatment of pulmonary edema [6].
In this case, there was concomitant use of steroids
for lung maturation, together with ritodrine, which
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increased the suspicion of noncardiogenic pulmonary
edema, as the shortness of breath, cough, sweating,
and deterioration of consciousness started after the
administration of steroid therapy for lung maturation.
Hyperventilation with inspiratory rales and chest X-ray
findings of increased pulmonary density in basal lobes
supported our clinical diagnosis. In spite of aggressive
treatment, the patient still died 10 hours later.
In conclusion, although preterm delivery is asso-
ciated with a risk of morbidity and mortality in the
newborn, the treatment of this condition also has its
inherent risks, which should not be overlooked. The use
of ritodrine, which has long been favored in the treat-
ment of preterm labor, may cause potentially lethal
pulmonary edema, especially with concomitant use of
steroids for fetal lung maturation.
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